Amgen Inc (AMGN) Received its Third Buy in a Row

By Jason Carr

After Oppenheimer and Goldman Sachs gave Amgen Inc (NASDAQ: AMGN) a Buy rating last month, the company received another Buy, this time from Morgan Stanley. Analyst Matthew Harrison maintained a Buy rating on Amgen Inc today and set a price target of $212. The company’s shares closed yesterday at $187.10.

According to, Harrison is a 4-star analyst with an average return of 7.9% and a 55.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Global Blood Therapeutics, and Alexion Pharmaceuticals.

Amgen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $209.55, implying an 12.0% upside from current levels. In a report issued on December 4, Oppenheimer also assigned a Buy rating to the stock with a $224 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $210.19 and a one-year low of $163.31. Currently, Amgen Inc has an average volume of 2.89M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.